



ELSEVIER
SAUNDERS

Surg Oncol Clin N Am
17 (2008) 701–708

SURGICAL
ONCOLOGY CLINICS
OF NORTH AMERICA

Index

Note: Page numbers of article titles are in **boldface** type.

A

- Ablation, local, for curative hepatic resection of bilobar colorectal metastases, 558–560
- Adenocarcinoma, pancreatic, treatment of, European perspective on, **569–586**
- Adhesion, cell, in prognosis of gastric carcinoma, 474
- Adjuvant therapy, for pancreatic adenocarcinoma, 577
systemic, for melanoma, 640–643
 chemotherapy, nonspecific
 immune stimulants, and
 vaccines, 640–641
 interferon-alpha, 641–643
 need for predictive factors, 643
- Anatomic resection, and parenchymal preservation in liver resection for hepatocellular carcinoma, 617–618
- Apoptosis, in prognosis of gastric carcinoma, 473–474
- Autoantibodies, as predictive factors in adjuvant therapy for melanoma, 643

B

- Biliary drainage, preoperative, in pancreatic adenocarcinoma, 571–572
- Bilobar distribution, of colorectal liver metastases, prognostic value of, 554
- Biopsy, sentinel lymph node, in breast cancer, **673–699**
- Bleeding, prevention of, in liver resection for hepatocellular carcinoma, 618–622
- Breast cancer, sentinel lymph node biopsy in, **673–699**
 enhanced pathology, 679–682
 false-negative rate, 676
 identification of sentinel node
 and type of injection,
 675–676

- intraoperative examination,
 677–679
morbidity, 676–677
predicting involvement of non-sentinel lymph nodes,
 682–683
prognostic significance of
 micrometastases, 683–684
role in special circumstances,
 684–691
 ductal carcinoma in situ,
 684–685
for multicentric disease,
 686–687
internal mammary sentinel
 lymph node biopsy,
 690–691
neoadjuvant chemotherapy,
 687–688
preoperative identification
 of node involvement
 by ultrasound,
 689–690
repeat, for recurrent breast
 cancer, 688–689
tumor diameter, 685–686

C

- Cell adhesion, in prognosis of gastric carcinoma, 474
- Cell cycle, in prognosis of gastric carcinoma, 473–474
- Chemoradiotherapy, for advanced cancer of esophagus and gastroesophageal junction, definitive, 496–498
 induction, 492–495
tumor response to, in rectal cancer,
 545–546
- Chemotherapy, as adjuvant therapy for melanoma, 640–641
for rectal cancer, 543–544
for soft-tissue sarcoma, 658–661
 adjuvant, 658
 chemoradiation, 659–660

- Chemotherapy (*continued*)
 for advanced or metastatic, 660
 postoperative, 658–659
 induction, for advanced cancer of
 esophagus and gastroesophageal
 junction, 491–492
 neoadjuvant, for curative hepatic
 resection of bilobar colorectal
 metastases, 557–558
 use of sentinel lymph node biopsy
 in breast cancer patients
 undergoing, 687–688
 palliative, for pancreatic
 adenocarcinoma, 579–580
- Chronic liver disease, liver resection for
 hepatocellular carcinoma with, 610
 results of, 624–627
- Circulating tumor cells, in prognosis of
 gastric carcinoma, 475–476
- Colorectal cancer. *See also* Rectal cancer.
 advanced, staging of, **503–517**
 bilobar colorectal liver metastases,
553–568
 evaluation of hepatic functional
 reserve, 555–556
 hepatic resection, justification
 for, 556–557
 innovative approaches allowing
 curative hepatic resection,
 557–562
 increasing the volume of the
 remnant liver
 parenchyma, 560–662
 reducing the extent of
 hepatic resection,
 557–560
 preoperative assessment of
 hepatic involvement,
 554–555
 prognostic factors, 554
 surgical strategy, 563–564
 laparoscopic resection for, **519–531**
 conversion rate, 524
 cost effectiveness, 527–528
 disease-free survival and
 recurrence, 525
 early postoperative recovery
 following, 521
 for rectal cancer, 525–527
 learning curve, 528
 oncologic quality of resection,
 524–525
 postoperative mortality, 521–524
 vs. open surgery, randomized
 trials of, 520–521
- Cost effectiveness, of laparoscopic resection
 for colorectal cancer, 527–528

D

- Diameter, tumor, impact on sentinel lymph
 node biopsy in breast cancer,
 685–686
- Drainage, biliary, preoperative, in
 pancreatic adenocarcinoma, 571–572
- Ductal carcinoma in situ, role of sentinel
 lymph node biopsy in, 684–685

E

- Elective lymph node dissection, for
 melanoma, 636
- Embolization, portal vein, for curative
 hepatic resection of bilobar colorectal
 metastases, 560–561
- Esophagus, advanced cancer of
 gastroesophageal junction and,
 multidisciplinary treatment of,
485–502
 definitive chemoradiotherapy,
 496–498
 induction neoadjuvant therapy,
 490–495
 induction
 chemoradiotherapy,
 492–495
 induction chemotherapy,
 491–492
 patient selection for
 primary surgery
 vs. induction therapy,
 495–496
 preoperative radiotherapy,
 490–491
 primary surgery, 486–489

G

- Gastric carcinoma, prognostic factors in,
467–483
 conventional, 468–470
 grading, 469
 lymphatic and vascular
 invasion, 469–470
 TNM staging system,
 468–469
 tumor site, 468
 type of surgery, 470
 molecular, 470–476
 cell adhesion, 474
 cell cycle, apoptosis, and
 p53, 473–474
 circulating tumor cells,
 475–476
 gene expression profiles,
 474–475

Download English Version:

<https://daneshyari.com/en/article/3998996>

Download Persian Version:

<https://daneshyari.com/article/3998996>

[Daneshyari.com](https://daneshyari.com)